Bladder Muscle Dysfunction Overactive — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for bladder muscle dysfunction overactive. 34 active patents protecting 2 drugs from 2+ originators. First major cliff: 2027. Daily refresh.

2
Approved drugs
34
Active US patents
64/100
Avg vulnerability
$1.8B
Annual revenue covered

Originators in Bladder Muscle Dysfunction Overactive

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Apgdi 22 patents Pfizer 12 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating bladder muscle dysfunction overactive. Each bar = one year. Y-axis scaled to peak year (12 patents).

12
27
2
28
10
29
8
30
2
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Myrbetriq
MIRABEGRON
 Apgdi 22 53 $1.8B 2028-10-30
Toviaz
Fesoterodine Fumarate
 Pfizer 12 74 — 2027-06-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7807715 Toviaz method of use 80 2027-06-07
8088398 Toviaz method of use 80 2027-06-07
7807715 Toviaz method of use 80 2027-06-07
8088398 Toviaz method of use 80 2027-06-07
7807715 Toviaz other 75 2027-12-07
8501723 Toviaz other 75 2027-12-07
8088398 Toviaz other 75 2027-12-07
8501723 Toviaz other 75 2027-12-07
8088398 Toviaz other 75 2027-12-07
7807715 Toviaz other 75 2027-12-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12059409 Myrbetriq formulation 44 2029-09-28
12059409 Myrbetriq formulation 44 2029-09-28
10058536 Myrbetriq other 45 2036-09-30
10058536 Myrbetriq method of use 45 2036-03-31
12097189 Myrbetriq other 51 2030-03-28
12059409 Myrbetriq other 51 2030-03-28
11707451 Myrbetriq other 51 2030-03-28
11707451 Myrbetriq other 51 2030-03-28
12097189 Myrbetriq other 51 2030-03-28
10842780 Myrbetriq other 51 2030-03-28

Related